References
Key articles
European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433-60.Full text Abstract
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Full text Abstract
Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021 Sep;70(9):1782-94.Full text Abstract
Centers for Disease Control and Prevention. Viral hepatitis: hepatitis D. June 2020 [internet publication].Full text
Reference articles
1. European Association for the Study of the Liver. EASL clinical practice guidelines on hepatitis delta virus. J Hepatol. 2023 Aug;79(2):433-60.Full text Abstract
2. Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Full text Abstract
3. Kamili S, Drobeniuc J, Mixson-Hayden T, et al. Delta hepatitis: toward improved diagnostics. Hepatology. 2017 Dec;66(6):1716-8.Full text Abstract
4. Walker PJ, Siddell SG, Lefkowitz EJ, et al. Changes to virus taxonomy and to the International Code of Virus Classification and Nomenclature ratified by the International Committee on Taxonomy of Viruses (2021). Arch Virol. 2021 Sep;166(9):2633-48.Full text Abstract
5. Majeed NA, Hitawala AA, Heller T, et al. Diagnosis of HDV: from virology to non-invasive markers of fibrosis. Liver Int. 2023 Aug;43(suppl 1):31-46.Full text Abstract
6. Casey JL, Brown TL, Colan EJ, et al. A genotype of hepatitis D virus that occurs in northern South America. Proc Natl Acad Sci U S A. 1993 Oct 1;90(19):9016-20.Full text Abstract
7. Wu JC, Choo KB, Chen CM, et al. Genotyping of hepatitis D virus by restriction-fragment length polymorphism and relation to outcome of hepatitis D. Lancet. 1995 Oct 7;346(8980):939-41. Abstract
8. Wu JC, Chen TZ, Huang YS, et al. Natural history of hepatitis D viral superinfection: significance of viremia detected by polymerase chain reaction. Gastroenterology. 1995 Mar;108(3):796-802. Abstract
9. Gaeta GB, Stroffolini T, Chiaramonte M, et al. Chronic hepatitis D: a vanishing disease? An Italian multicenter study. Hepatology. 2000 Oct;32(4 pt 1):824-7.Full text Abstract
10. Urban S, Neumann-Haefelin C, Lampertico P. Hepatitis D virus in 2021: virology, immunology and new treatment approaches for a difficult-to-treat disease. Gut. 2021 Sep;70(9):1782-94.Full text Abstract
11. Stockdale AJ, Kreuels B, Henrion MYR, et al. The global prevalence of hepatitis D virus infection: systematic review and meta-analysis. J Hepatol. 2020 Sep;73(3):523-32.Full text Abstract
12. Centers for Disease Control and Prevention. Viral hepatitis: hepatitis D. June 2020 [internet publication].Full text
13. Sureau C, Negro F. The hepatitis delta virus: replication and pathogenesis. J Hepatol. 2016 Apr;64(1 suppl):S102-S116. Abstract
14. Wang CJ, Chen PJ, Wu JC, et al. Small-form hepatitis B surface antigen is sufficient to help in the assembly of hepatitis delta virus-like particles. J Virol. 1991 Dec;65(12):6630-6.Full text Abstract
15. Taylor JM. Infection by hepatitis delta virus. Viruses. 2020 Jun 16;12(6):648.Full text Abstract
16. Negro F. Hepatitis D virus coinfection and superinfection. Cold Spring Harb Perspect Med. 2014 Nov 3;4(11):a021550.Full text Abstract
17. Sausen DG, Shechter O, Bietsch W, et al. Hepatitis B and hepatitis D viruses: a comprehensive update with an immunological focus. Int J Mol Sci. 2022 Dec 15;23(24):15973.Full text Abstract
18. Smedile A, Farci P, Verme G, et al. Influence of delta infection on severity of hepatitis B. Lancet. 1982 Oct 30;2(8305):945-7. Abstract
19. Cole SM, Gowans EJ, Macnaughton TB, et al. Direct evidence for cytotoxicity associated with expression of hepatitis delta virus antigen. Hepatology. 1991 May;13(5):845-51. Abstract
20. Shirvani-Dastgerdi E, Tacke F. Molecular interactions between hepatitis B virus and delta virus. World J Virol. 2015 May 12;4(2):36-41.Full text Abstract
21. Pollicino T, Raffa G, Santantonio T, et al. Replicative and transcriptional activities of hepatitis B virus in patients coinfected with hepatitis B and hepatitis delta viruses. J Virol. 2011 Jan;85(1):432-9.Full text Abstract
22. Lin HH, Lee SS, Yu ML, et al. Changing hepatitis D virus epidemiology in a hepatitis B virus endemic area with a national vaccination program. Hepatology. 2015 Jun;61(6):1870-9. Abstract
23. Hercun J, Koh C, Heller T. Hepatitis delta: prevalence, natural history, and treatment options. Gastroenterol Clin North Am. 2020 Jun;49(2):239-52. Abstract
24. Goldstein ST, Alter MJ, Williams IT, et al. Incidence and risk factors for acute hepatitis B in the United States, 1982-1998: implications for vaccination programs. J Infect Dis. 2002 Mar 15;185(6):713-9.Full text Abstract
25. Rashti R, Alavian SM, Moradi Y, et al. Global prevalence of HCV and/or HBV coinfections among people who inject drugs and female sex workers who live with HIV/AIDS: a systematic review and meta-analysis. Arch Virol. 2020 Sep;165(9):1947-58. Abstract
26. Da BL, Rahman F, Lai WC, et al. Risk factors for delta hepatitis in a North American cohort: who should be screened? Am J Gastroenterol. 2021 Jan 1;116(1):206-9. Abstract
27. Degenhardt L, Peacock A, Colledge S, et al. Global prevalence of injecting drug use and sociodemographic characteristics and prevalence of HIV, HBV, and HCV in people who inject drugs: a multistage systematic review. Lancet Glob Health. 2017 Dec;5(12):e1192-e1207.Full text Abstract
28. Falla AM, Hofstraat SHI, Duffell E, et al. Hepatitis B/C in the countries of the EU/EEA: a systematic review of the prevalence among at-risk groups. BMC Infect Dis. 2018 Feb 12;18(1):79.Full text Abstract
29. Sellier PO, Maylin S, Brichler S, et al. Hepatitis B virus - hepatitis D virus mother-to-child co-transmission: a retrospective study in a developed country. Liver Int. 2018 Apr;38(4):611-8. Abstract
30. Bond WW, Favero MS, Petersen NJ, et al. Survival of hepatitis B virus after drying and storage for one week. Lancet. 1981 Mar 7;1(8219):550-1. Abstract
31. Kharsa G, Degott C, Degos F, et al. Fulminant hepatitis in renal transplant recipients. The role of the delta agent. Transplantation. 1987 Aug;44(2):221-3.Full text Abstract
32. World Health Organization. Hepatitis D fact sheet. July 2023 [internet publication].Full text
33. Aldabe R, Suárez-Amarán L, Usai C, et al. Animal models of chronic hepatitis delta virus infection host-virus immunologic interactions. Pathogens. 2015 Feb 12;4(1):46-65.Full text Abstract
34. Farci P, Niro GA. Clinical features of hepatitis D. Semin Liver Dis. 2012 Aug;32(3):228-36.Full text Abstract
35. Smedile A, Dentico P, Zanetti A, et al. Infection with the delta agent in chronic HBsAg carriers. Gastroenterology. 1981 Dec;81(6):992-7. Abstract
37. Lettau LA, McCarthy JG, Smith MH, et al. Outbreak of severe hepatitis due to delta and hepatitis B viruses in parenteral drug abusers and their contacts. N Engl J Med. 1987 Nov 12;317(20):1256-62. Abstract
38. Trey C, Davidson CS. The management of fulminant hepatic failure. Prog Liver Dis. 1970;3:282-98. Abstract
39. Gimson AE, O'Grady J, Ede RJ, et al. Late onset hepatic failure: clinical, serological and histological features. Hepatology. 1986 Mar-Apr;6(2):288-94. Abstract
40. Bernuau J, Rueff B, Benhamou JP. Fulminant and subfulminant liver failure: definitions and causes. Semin Liver Dis. 1986 May;6(2):97-106. Abstract
41. European Association for the Study of the Liver. EASL 2017 clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98.Full text Abstract
42. Abara WE, Qaseem A, Schillie S, et al. Hepatitis B vaccination, screening, and linkage to care: best practice advice from the American College of Physicians and the Centers for Disease Control and Prevention. Ann Intern Med. 2017 Dec 5;167(11):794-804.Full text Abstract
43. Pondé RAA. The serological markers of acute infection with hepatitis A, B, C, D, E and G viruses revisited. Arch Virol. 2017 Dec;162(12):3587-602. Abstract
44. Heimbach JK, Kulik LM, Finn RS, et al. AASLD guidelines for the treatment of hepatocellular carcinoma. Hepatology. 2018 Jan;67(1):358-80.Full text Abstract
45. Wasley A, Miller JT, Finelli L, et al. Surveillance for acute viral hepatitis - United States, 2005. MMWR Surveill Summ. 2007 Mar 16;56(3):1-24. Abstract
46. Xiao H, Shi M, Xie Y, et al. Comparison of diagnostic accuracy of magnetic resonance elastography and Fibroscan for detecting liver fibrosis in chronic hepatitis B patients: a systematic review and meta-analysis. PLoS One. 2017 Nov 6;12(11):e0186660.Full text Abstract
47. Mack CL, Adams D, Assis DN, et al. Diagnosis and management of autoimmune hepatitis in adults and children: 2019 practice guidance and guidelines from the American Association for the Study of Liver Diseases. Hepatology. 2020 Aug;72(2):671-722.Full text Abstract
48. Krawitt EL. Autoimmune hepatitis. N Engl J Med. 2006 Jan 5;354(1):54-66. Abstract
49. McElvaney NG, Stoller JK, Buist AS, et al. Baseline characteristics of enrollees in the National Heart, Lung and Blood Institute Registry of alpha 1-antitrypsin deficiency. Alpha 1-Antitrypsin Deficiency Registry Study Group. Chest. 1997 Feb;111(2):394-403. Abstract
50. Bedossa P, Poynard T. An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group. Hepatology. 1996 Aug;24(2):289-93. Abstract
51. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol. 1995 Jun;22(6):696-9. Abstract
52. Miller JM, Binnicker MJ, Campbell S, et al. A guide to utilization of the microbiology laboratory for diagnosis of infectious diseases: 2018 update by the Infectious Diseases Society of America and the American Society for Microbiology. Clin Infect Dis. 2018 Aug 31;67(6):e1-e94.Full text Abstract
53. Belli LS, Berenguer M, Cortesi PA, et al. Delisting of liver transplant candidates with chronic hepatitis C after viral eradication: a European study. J Hepatol. 2016 Sep;65(3):524-31. Abstract
54. Martini S, Tandoi F, Romagnoli R, et al. Liver transplantation in hepatitis B/hepatitis D (delta) virus coinfected recipients. Transplantation. 2022 Oct 1;106(10):1935-9. Abstract
55. National Institute for Health and Care Excellence. Hepatitis B (chronic): diagnosis and management. October 2017 [internet publication].Full text
56. Brancaccio G, Gaeta GB. Treatment of chronic hepatitis due to hepatitis B and hepatitis delta virus coinfection. Int J Antimicrob Agents. 2019 Dec;54(6):697-701. Abstract
57. Sandmann L, Wedemeyer H. Interferon-based treatment of chronic hepatitis D. Liver Int. 2023 Aug;43 Suppl 1:69-79.Full text Abstract
58. National Institute for Health and Care Excellence. Bulevirtide for treating chronic hepatitis D. June 2023 [internet publication].Full text
59. Wedemeyer H, Schöneweis K, Bogomolov P, et al. Safety and efficacy of bulevirtide in combination with tenofovir disoproxil fumarate in patients with hepatitis B virus and hepatitis D virus coinfection (MYR202): a multicentre, randomised, parallel-group, open-label, phase 2 trial. Lancet Infect Dis. 2023 Jan;23(1):117-29. Abstract
60. Wedemeyer H, Aleman S, Brunetto MR, et al. A phase 3, randomized trial of bulevirtide in chronic hepatitis D. N Engl J Med. 2023 Jul 6;389(1):22-32. Abstract
61. Koh C, Canini L, Dahari H, et al. Oral prenylation inhibition with lonafarnib in chronic hepatitis D infection: a proof-of-concept randomised, double-blind, placebo-controlled phase 2A trial. Lancet Infect Dis. 2015 Oct;15(10):1167-74. Abstract
62. Yurdaydin C, Keskin O, Kalkan Ç, et al. Optimizing lonafarnib treatment for the management of chronic delta hepatitis: The LOWR HDV-1 study. Hepatology. 2018 Apr;67(4):1224-36. Abstract
63. ClinicalTrials.gov. Study of the efficacy and safety of lonafarnib/ritonavir with and without pegylated interferon-alfa-2a (D-LIVR). NCT03719313. April 2023 [internet publication].Full text
64. Centers for Disease Control and Prevention. Adult immunization schedule by age:recommendations for ages 19 years or older, United States, 2023. April 2023 [internet publication].Full text
65. Kamal H, Westman G, Falconer K, et al. Long-term study of hepatitis delta virus infection at secondary care centers: the impact of viremia on liver-related outcomes. Hepatology. 2020 Oct;72(4):1177-90.Full text Abstract
66. Romeo R, Del Ninno E, Rumi M, et al. A 28-year study of the course of hepatitis delta infection: a risk factor for cirrhosis and hepatocellular carcinoma. Gastroenterology. 2009 May;136(5):1629-38.Full text Abstract
67. Fattovich G, Giustina G, Christensen E, et al. Influence of hepatitis delta virus infection on morbidity and mortality in compensated cirrhosis type B. The European Concerted Action on Viral Hepatitis (Eurohep). Gut. 2000 Mar;46(3):420-6.Full text Abstract
68. Manesis EK, Vourli G, Dalekos G, et al. Prevalence and clinical course of hepatitis delta infection in Greece: a 13-year prospective study. J Hepatol. 2013 Nov;59(5):949-56. Abstract
69. Gupta S, Bent S, Kohlwes J. Test characteristics of alpha-fetoprotein for detecting hepatocellular carcinoma in patients with hepatitis C. A systematic review and critical analysis. Ann Intern Med. 2003 Jul 1;139(1):46-50.Full text Abstract
70. Soresi M, Magliarisi C, Campagna P, et al. Usefulness of alpha-fetoprotein in the diagnosis of hepatocellular carcinoma. Anticancer Res. 2003 Mar-Apr;23(2c):1747-53. Abstract
Use of this content is subject to our disclaimer